The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of July 24, 2017.
Transcript
Hi, I’m Kelly Davio for the Center for Biosimilars, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of July 24.
Number 5: FDA Commissioner, Dr Scott Gottlieb, along with the acting director of the Federal Trade Commission, testified before the House Judiciary Committee on Thursday concerning antitrust issues and the FDA approval process.
Number 4: A recent report on the current pipeline of biopharmaceuticals shows 749 projects under development for diabetes and diabetes-related complications.
Number 3: The House of Representatives passed the Medicare Part B Improvement Act, but the bill could face funding issues after CMS proposed a cut to payment for home healthcare.
Number 2: The prospective adalimumab biosimilar CinnoRA was shown in a recent phase 3 trial to be noninferior to Humira.
And finally, Number 1: This week, Merck announced the US launch of its biosimilar infliximab, Renflexis, at a 35% discount to Remicade.
Read these articles and more at centerforbiosimilars.com.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims
October 23rd 2024At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen industry collaboration, with Sarah Yim, MD, of the FDA, emphasizing education's key role in building trust and adoption.